Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another...


Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder treatment Viibryd, which sent shares up more than 50%. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs